Today, Abeona Therapeutics Inc. (ABEO) PT Set at $14.00 by Maxim Group

Today, Abeona Therapeutics Inc. (ABEO) PT Set at $14.00 by Maxim Group

Abeona Therapeutics Inc. (NASDAQ:ABEO) received a $14.00 price target from Maxim Group in a note issued to investors on Wednesday. The brokerage currently has a a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price suggests a potential upside of 113.41% from the stock’s current price.

ABEO has been the topic of several other research reports. Cantor Fitzgerald started coverage on shares of Abeona Therapeutics in a research note on Wednesday, September 7th. They set a “buy” rating and a $21.00 target price on the stock. Zacks Investment Research cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 12th. FBR & Co reaffirmed a “buy” rating and set a $15.00 target price on shares of Abeona Therapeutics in a research note on Friday, August 26th. Finally, Rodman & Renshaw reissued a “buy” rating and set a $17.00 price target on shares of Abeona Therapeutics in a research report on Sunday, August 21st. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $14.50.

Abeona Therapeutics (NASDAQ:ABEO) opened at 6.56 on Wednesday. The firm’s 50-day moving average is $5.15 and its 200 day moving average is $3.38. Abeona Therapeutics has a one year low of $2.05 and a one year high of $7.00. The company’s market capitalization is $220.06 million.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.06. Abeona Therapeutics had a negative return on equity of 30.84% and a negative net margin of 2,177.03%. On average, equities analysts expect that Abeona Therapeutics will post ($0.73) EPS for the current fiscal year.

In related news, Director Todd Wider acquired 5,000 shares of Abeona Therapeutics stock in a transaction that occurred on Tuesday, September 20th. The shares were purchased at an average cost of $5.48 per share, for a total transaction of $27,400.00. Following the acquisition, the director now owns 75,000 shares in the company, valued at $411,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 13.00% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the stock. Sabby Management LLC raised its stake in shares of Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock valued at $855,000 after buying an additional 34,108 shares during the period. Geode Capital Management LLC raised its stake in shares of Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 10,082 shares during the period. Royce & Associates LP raised its stake in shares of Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock valued at $963,000 after buying an additional 76,678 shares during the period. Finally, BlackRock Fund Advisors raised its stake in shares of Abeona Therapeutics by 8.5% in the first quarter. BlackRock Fund Advisors now owns 302,262 shares of the biopharmaceutical company’s stock valued at $774,000 after buying an additional 23,734 shares during the period. Hedge funds and other institutional investors own 19.95% of the company’s stock.

Abeona Therapeutics Company Profile

Related posts

Leave a Comment